DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for …
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) …
Insmed Ranks No. 1 on Science’s 2023 Top Biopharma Employers List
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of …
